23andMe Holding Co.

Good day, and welcome to 23andMe's fiscal year 2023 third quarter financial results conference call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the prayer marks, there will be a question and answer session. I would now like to turn the call over to Maeve Connington at Argo Partners to lead off the call. Thank you. Please go ahead.

Thank you, Justin. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued this afternoon reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event. Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for a future period, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section titled Forward-Looking Statements in our press release, which applies to this call. Also, please refer to our SEC filings, which can be found on our website and the SEC's website, for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release. Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder, and Joe Selfavage, our Interim Chief Financial and Accounting Officer. Kenneth Hillen, our Chief Therapeutics Officer, will join us for Q&A.

And with that, I'll turn the call over to Anne. Thank you.